SMART BIOMATERIALS

HOME COMPANY PRODUCTS R&D NEWS CONTACT

17th Interdisciplinary Research Conference on Biomaterials

Calcium phosphate biomaterials for a local-delivery of bisphosphonate:
Therapeutic approach for the pathologic bone disorder

Calcium phosphate (CaP) biomaterials such as calcium deficient apatite (CDA) or β-tricalcium phosphate (β-TCP) have been used as bone substitutes. At present, we investigate the capacity of these CaP to release locally drugs. Bisphosphonates (BP) are antiresorptive agents largely used in clinical treatment in osteoporosis. Our laboratory has reported that the reaction of CaP powders with aqueous zoledronate can result in different association modes between the two components (1).

Through a in vitro osteoclastic model (2), this study was designed to evaluate the in vitro bioactivity of two innovative bone drug delivery system (DDS), based on different association of zoledronate on PCa (CDA or β-TCP) matrices.

Quantitative analysis of the resorptive activity of osteoclasts indicated that Zoledronate-loaded CaP induced an almost complete inhibition of dentin slice surface resorbed, similar to that obtained with 10-6 mol.L-1 Zoledronate. Concerning osteoblastic cells, data showed the absence of cytotoxicity for both system in terms of proliferation and activity cellular.

These data demonstrate that both DDS were effective for release of Zoledronate at doses which inhibiting osteoclastic resorption. This study shows that the two vehicle materials (CDA and β-TCP) are good candidate for releasing BP molecules which will allow to develop with porous ceramic forms (β-TCP) or injectable suspension (CDA).

Reference :
1. Josse S, et al. Biomaterials. 2005 ;26:2037-2080
2. Grimandi G & al, Microsc Res tech. 2006; 69:606-12

Download pdf